AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, announced an expansion of its blood-based testing capabilities in partnership with EmeritusDX, a rapidly growing cancer diagnostics and information company. The two companies are building out their best-in-class product portfolios and respective infrastructures to meet growing clinical demand for non-invasive testing technologies.

A key milestone in this expansion is the installation of the Promega Maxwell RSC system at EmeritusDX, enabling consistent, high-throughput extraction of microRNAs (miRNAs) from blood samples. This capability will power AccuStem’s MSC test, the first diagnostic on the market to use miRNAs to more accurately stratify lung nodules according to their risk of malignancy. By offering this novel test that has a strong foundation of data published in top-tier scientific journals, the companies aim to deliver value to patients and their care teams as well as long-term differentiation in the diagnostics landscape.

“We continue to see significant progress with the MSC technology transfer into EmeritusDX’s laboratories,” added Wendy Blosser, Chief Executive Officer of AccuStem Sciences. “With the right infrastructure and teams in place, we are accelerating the path to market for MSC and laying the groundwork for additional tests in the future. This is about delivering reliable, innovative solutions to patients while also creating value for our stakeholders.”

To further support growth, EmeritusDX has expanded its sales force by 35% and launched the Syntara™ platform, which integrates biomarker data, clinical factors, and other key inputs to help physicians develop personalized treatment strategies for patients with hematologic diseases. The launch of Syntara™ reflects the growing demand for tools that combine actionable insights with innovative diagnostics to improve patient care.

“These initiatives represent both a clinical and commercial inflection point,” said Robert Embree, Chief Executive Officer of EmeritusDX. “By investing in cutting-edge technology and specialized expertise, we are creating a scalable foundation for innovation that strengthens our competitive position, supports physicians, and ultimately improves patient outcomes. Blood-based testing is at the heart of this vision, and we see it as a core driver of our growth.”